the present invention provides novel therapeutic applications of low dose naltrexone (ldn). said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of toll-like receptor 9 (tlr9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized. chronic inflammation and tlr9 overexpression are characteristics of a number of disorders, including certain cancers. accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterized by tlr9 overexpression and / or overactivity of tlr9-mediated signalling. the present invention also provides novel uses of naltrexone in the supportive care of a subject having a tumor / cancer, and methods of treating and providing supportive care for a subject, including the administration of naltrexone. Patent Application: "Naltrexone Cancer Treatment" The present invention is concerned with providing novel low dose therapeutic applications of naltrexone (ldn). said applications have been determined in view of the discovery by the present inventors that naltrexone acts as a toll 9-like receptor antagonist (tlr9), an innate immunoreceptor that evokes the production of inflammatory cytokines when it is agonized. Chronic inflammation and overexpression of Tlr9 are characteristic of numerous disorders that include certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterized by tlr9 overexpression and / or tlr9-mediated signaling overactivity. The present invention also provides novel uses of naltrexone in palliative care of a subject having a tumor / cancer and methods of treating and providing palliative care for a subject comprising administering naltrexone.the present invention provides novel therapeutic applications of low dose naltrexone (ldn). said applications have been determined in ligh
